Church & Dwight (CHD) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
5 May, 2026Executive summary
Q1 2026 net sales rose 0.2% to $1,469.3M, exceeding expectations of a 1% decline, driven by 5.0% organic sales growth and strong volume gains across all divisions, supported by the Touchland acquisition and innovation.
Adjusted EPS increased 4.4% to $0.95, surpassing the $0.92 outlook, with reported EPS at $0.91.
Gross margin expanded 130–140 bps to 46.4%, reflecting productivity gains, favorable mix, and acquisition benefits.
Strong brand performance and innovation, with significant distribution gains and market share expansion across categories.
Operating income was $291.0M, down 1.5% year-over-year, with margin decline due to increased SG&A and marketing investments.
Financial highlights
Organic sales growth of 5% year-over-year, with volume up 5.3% and negative price/mix of 0.3%.
Net income for Q1 2026 was $216.3M, down from $220.1M in Q1 2025.
Adjusted income from operations was $302.6M, flat versus prior year, as higher gross margin was offset by increased marketing and SG&A.
Cash flow from operations was $174.8M; capital expenditures were $31.9M.
Marketing expense was 9.5% of sales, up 20 basis points year-over-year.
Outlook and guidance
Full-year 2026 organic sales growth guidance reiterated at 3–4%; reported sales expected to decline 1.5–0.5% due to prior portfolio actions.
Adjusted EPS growth expected at 5–8% for 2026; reported EPS up 18–22%.
Full-year gross margin expansion of ~100 bps expected; cash from operations forecast at $1.15B.
Q2 2026 guidance: reported sales to decline ~1%, organic sales growth ~3%, gross margin expansion of 50 bps, adjusted EPS of $0.88.
Capital expenditures for 2026 projected at $130M, focused on manufacturing capacity and ERP investments.
Latest events from Church & Dwight
- Key votes include director elections, executive pay, auditor ratification, and a written consent proposal.CHD
Proxy filing19 Mar 2026 - Board recommends all director nominees, pay, and auditor; opposes written consent proposal.CHD
Proxy filing19 Mar 2026 - 2026 targets 3–4% organic sales and 5–8% EPS growth, led by power brands and innovation.CHD
Consumer Analyst Group of New York Conference (CAGNY) 202618 Feb 2026 - Q2 sales, margins, and EPS beat expectations; growth slowed, but APAC and innovation advanced.CHD
Q2 20242 Feb 2026 - 2026 targets 3–4% organic sales growth and 5–8% EPS growth, led by innovation and portfolio focus.CHD
Q4 2025 & Analyst Day 20261 Feb 2026 - 2024 outlook targets strong sales and EPS growth, fueled by innovation and global expansion.CHD
2024 dbAccess Global Consumer Conference31 Jan 2026 - Power brands, innovation, and disciplined M&A fuel growth across U.S. and international markets.CHD
Barclays 17th Annual Global Consumer Staples Conference22 Jan 2026 - Q3 organic growth and margin gains were offset by a $357.1M vitamin business impairment.CHD
Q3 202417 Jan 2026 - 2024 delivered strong growth and cash flow; 2025 targets further organic and EPS gains.CHD
Q4 2024 & Investor Day 20259 Jan 2026